The Most Important Life Saving Research

Childhood Cancer Canada supports C17 Council, a national organization of childhood cancer and blood disease program in Canada. Comprised of leading pediatric oncologists and hematologist, C17 is dedicated to childhood cancer and advocating for policies to improve outcomes and quality of life for children.

Childhood Cancer Canada also funds sequencing of hard-to-cure childhood cancers through the PROFYLE (PRecision Oncology For Young peopLE) program to identify new therapies that are tailored to each patient and to improve the outcomes in hard-to-cure childhood cancers. PROFYLE is the national multidisciplinary program that translates genetic sequencing into new treatments for children, adolescents and young adults with hard-to-cure cancer.

“Over 80% of children with cancer can now have a cure. However, many of these children will have serious health issues later in life. New treatments such as immunotherapy and precision cancer medicine offer the hope of more cures with fewer serious side effects.”

Dr. Jim Whitlock,
Pediatric Oncologist,
Chair of C17 Council,
Co-Lead of the PROFYLE Therapeutics Node,
Head Haematology/Oncology at The Hospital for Sick Children,
Board of Directors, Childhood Cancer Canada